Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. - Wikidata - awgldk - TriplyDB

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.

http://www.wikidata.org/entity/Q33964804

about

Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1 ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2 Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases Abnormal visual gain control in a Parkinson's disease model.Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.Brain Penetrant LRRK2 Inhibitor.Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity Combination therapies: The next logical Step for the treatment of synucleinopathies?LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.LRRK2 mutations and neurotoxicant susceptibility Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.Genetic insights into sporadic Parkinson's disease pathogenesis.Mechanisms of LRRK2-mediated neurodegeneration.Novel models for assessing blood-brain barrier drug permeation.Kinase signaling dysfunction in Parkinson's disease: a reverse genetic approach in Drosophila.Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.Genetic determinants of neuronal vulnerability to apoptosis.Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.New synaptic and molecular targets for neuroprotection in Parkinson's disease.Parkinson's disease: an update on pathogenesis and treatment.Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease.Animal models of Parkinson's disease: a gateway to therapeutics?Targeting leucine-rich repeat kinase 2 in Parkinson's disease.LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis Use of Caenorhabditis elegans as a model to study Alzheimer's disease and other neurodegenerative diseases.LRRK2 pathobiology in Parkinson's disease.Combating neurodegenerative disease with chemical probes and model systems.Chemotherapeutic xCT inhibitors sorafenib and erastin unraveled with the synaptic optogenetic function analysis tool Drug repurposing for aging research using model organisms.Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.

P2860

Q22242985-D992D8C6-D3FF-4B82-98C1-A2226ED86AC7 Q24301357-EBCA6708-5CAA-4CF5-AC68-C96E841D8CD5 Q24307742-16BFF082-E571-4382-839A-467CCBFC65FF Q26776093-392C37C0-8186-49AF-AD67-F82DE81B08B5 Q27013695-F192B605-BEFA-4B9B-8FC6-A474E4B56A77 Q27026262-54A2DFD6-25D1-4400-B1E8-51D85722ECAF Q27334018-828F4A8A-95B6-40E9-82E8-71EE6DCCA72F Q28119192-66C947D0-955B-4914-92D0-5CBA6DD00DD7 Q30585664-E9793646-2FCB-43F1-9A1C-4E700A356222 Q34325540-5ABD9429-961C-4257-B7C1-CCEC209FB2E9 Q35913800-297349FB-61B0-43E0-A34F-87AA24402927 Q36015579-74DCB64F-02C1-491E-BC40-19438B8A256C Q36305876-FF77A336-705C-4083-86CA-FC4373C88045 Q36454426-4F294B88-C001-43A1-B569-1B14E331E490 Q36477677-F4C2A85D-816D-4933-A2B9-2BD99DC654B0 Q36563062-E9569157-875B-41B9-B435-C0304E7F69D1 Q36981223-DFEEAFD1-7863-47B0-8A01-3E5920E4040C Q37071013-CAB23058-688B-4135-AEF2-58300137616B Q37506492-EA08555C-B830-437E-92FE-6119413B2F31 Q37513500-6CC3B804-787B-4D98-9D36-D76454D9F61B Q37583402-29A6384A-43F0-4D73-A1A2-EB089F8960F0 Q37996364-C63C255C-467A-44DC-8B94-5028BD70FF54 Q37999058-1E50A25D-19C1-4C7D-9F9D-FB657818AEAB Q38001018-66933F0C-DE27-4B10-8B2C-2DF89CF6E4AE Q38009436-358A364E-73C0-4A6A-A8B2-B48DDED8AC4C Q38018496-53440C0E-AFE0-48F0-A445-E4AA54B39DEC Q38021865-821160E2-7D5A-4B1A-9102-5BD34556FA65 Q38038559-73871071-2E2E-412B-A81D-931A6FE1C839 Q38099279-B915C8A0-4CDE-4614-8B5D-9C1B232C4CE9 Q38112215-9CB40B6E-BB8E-413E-AF11-A8046073058B Q38155480-0941A4B8-A404-4F37-8235-0ADFE63B12BF Q38160939-81BC30EF-018C-4B6E-9949-60C2BF77F69F Q38218398-D244F959-D64D-416F-8336-32940BC1C86B Q38253642-FE75480B-D3A6-4358-B6BB-FC85F7998FB7 Q38253871-9A6DF740-B712-4F2C-9E7C-01B2B3DEFA62 Q38261089-8EF5C459-84F0-4DCF-9129-6B5B97B67E67 Q38611037-21E9FD4A-50A3-4E54-A400-8BA685D3FFFE Q38722916-07F84129-A218-42B3-9D19-BC83B3ED65AB Q39137358-DF5B7E6B-2FBE-4C50-B3B2-374FA50996AB Q39164937-4B57BD47-585C-43C6-A3DC-ED1BAF766BFF

P2860

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.

http://www.wikidata.org/entity/Q33964804

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Inhibitors of LRRK2 kinase att ...... la Parkinson's disease models.

@ast

Inhibitors of LRRK2 kinase att ...... la Parkinson's disease models.

@en

type

label

Inhibitors of LRRK2 kinase att ...... la Parkinson's disease models.

@ast

Inhibitors of LRRK2 kinase att ...... la Parkinson's disease models.

@en

prefLabel

Inhibitors of LRRK2 kinase att ...... la Parkinson's disease models.

@ast

Inhibitors of LRRK2 kinase att ...... la Parkinson's disease models.

@en

P1433

Q33964804-5568AB72-AD2E-43BE-BB0F-0B24017BCEBB

P1476

Q33964804-0188ABC3-6739-42AE-9608-DEC84A1F6A87

P2093

Q33964804-07787ADE-6EBD-4DDF-9E1E-99D910368CAA

Q33964804-0A1FCC3C-5D1C-41FE-BAF7-943DBC2F47DC

Q33964804-19D67A38-92CE-47E5-956D-4CADD92A3A81

Q33964804-20DDC8A3-8FD9-4781-8ABB-27CA677FA0D7

Q33964804-9052646A-EFF2-4DB6-8B4A-F7914E1CAADA

Q33964804-98580F8A-8A25-4BCC-985D-F7124D5066A6

Q33964804-B508E99D-A23A-47C2-A0A7-AE2AD6974070

Q33964804-FD1D3616-4942-41B1-B749-76F625D82B5E

P2860

Q33964804-01C7D1AD-053C-460B-96A6-15FD84BD3CAD

Q33964804-0E3B2020-ADC0-44B4-9BBB-934AA5EEDF1B

Q33964804-0F305B81-CBAA-45AC-83CD-E5197894F4C6

Q33964804-12AA4E35-6916-4E1F-9968-9908F9B853E6

Q33964804-1C72F226-2F41-4989-9F96-C31155BCD5C5

Q33964804-20F8DCE2-3144-4D11-B275-9883F8F433A6

Q33964804-299E6398-572D-4711-8C49-0E3B3A25307E

Q33964804-2A8EADF7-80A9-42B2-91F8-E02F263FD127

Q33964804-4B1BA378-7EEC-451F-B69A-09BC090E5217

Q33964804-5431E221-3A7D-418D-8B74-6B79B647DE2A

P304

Q33964804-B7F0CA08-7F4E-47DC-878E-7499D520712A

P31

Q33964804-0B001275-0504-48D3-B280-97A8639CF14F

P356

Q33964804-32EE0095-20E9-4BCE-A848-B23BBF53B174

P433

Q33964804-DCF5DCBD-CB19-44A6-B0CB-0352FA232073

P478

Q33964804-0459EE23-762F-4244-AC73-9F73F3A3EC8D

P50

Q33964804-22CF6419-5C72-4199-913E-38FBF82145FC

Q33964804-52BC10CF-DA67-4904-9018-79C51EAD4ADF

P577

Q33964804-BF0332FF-D70A-4542-AB65-5192BAADA884

P5875

Q33964804-BF6AAB38-56FC-458A-A8C4-FB637C563049

P698

Q33964804-B27D5F81-DD5D-4714-AD5C-C152E2791F19

P921

Q33964804-1BA3999C-343F-4026-89BE-0D91B9AC839C

Q33964804-955EF73A-AE9C-49B9-8FFE-A172B93CD6E4

Q33964804-D31FACFA-316F-45B0-8627-3D2DE98773A9

P932

Q33964804-B6027DB3-CDFD-4845-B8C5-95B1E93D6B4B

P356

P1433

Human Molecular Genetics

P1476

Inhibitors of LRRK2 kinase att ...... la Parkinson's disease models.

@en

P2093

Arpita Ray

http://www.w3.org/2001/XMLSchema#string

Byoung Dae Lee

http://www.w3.org/2001/XMLSchema#string

Dejun Yang

http://www.w3.org/2001/XMLSchema#string

Guy A Caldwell

http://www.w3.org/2001/XMLSchema#string

Kim A Caldwell

http://www.w3.org/2001/XMLSchema#string

Shusei Hamamichi

http://www.w3.org/2001/XMLSchema#string

Wanli W Smith

http://www.w3.org/2001/XMLSchema#string

Zhaohui Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Kinase activity of mutant LRRK2 mediates neuronal toxicity

The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro

Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity

The genetics of Caenorhabditis elegans

Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models

alpha-Synuclein locus triplication causes Parkinson's disease

A C. elegans mutant that lives twice as long as wild type

P304

3933-3942

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/DDR312

http://www.w3.org/2001/XMLSchema#string

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Valina L. Dawson

P577

2011-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51501321

http://www.w3.org/2001/XMLSchema#string

P698

21768216

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

Caenorhabditis elegans

P932

3177653

http://www.w3.org/2001/XMLSchema#string